Table 1.
AIC and BIC values for modeling overall survival.
| Overall Survival | Atezolizumab + Bevacizumab | Sorafenib | ||
|---|---|---|---|---|
|
|
|
|
||
| Model | AIC | BIC | AIC | BIC |
| Weibull (PH) | 1495.43 | 1510.7 | 761.93 | 771.25 |
| Weibull (AFT) | 1495.46 | 1510.73 | 761.92 | 771.24 |
| Log-normal | 1486.3 | 1501.57 | 755.63 | 764.95 |
| Log-logistic | 1491.07 | 1506.34 | 757.92 | 767.24 |
| Gen. Gamma | 1488.91 | 1507.99 | 757.6 | 770.02 |
| Gen. F | 1494.52 | 1517.43 | 760.52 | 776.05 |
| Gamma | 1493.31 | 1508.57 | 760.77 | 770.09 |
| Exponential | 1507.5 | 1518.95 | 762.77 | 768.98 |
AIC: Akaike information criterion; BIC: Bayesian information criterion.